

LIGAND PHARMACEUTICALS INC
 Form 4
 December 01, 2008

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 BVF PARTNERS L P/IL

2. Issuer Name and Ticker or Trading Symbol
 LIGAND PHARMACEUTICALS INC [LGND]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 ONE SANSOME STREET, 31ST FLOOR
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 11/26/2008

___ Director ___X___ 10% Owner
 ___ Officer (give title below) ___X___ Other (specify below)
 Indirect Beneficial Owner

SAN FRANCISCO, CA 94104

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___ Form filed by One Reporting Person
 ___X___ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/26/2008		P		226,000 (3)	A	\$ 1.93	11,695,653 (6)	I	See footnotes (1) (2)
Common Stock	11/26/2008		P		156,000 (4)	A	\$ 1.93	11,851,653 (6)	I	See footnotes (1) (2)
Common Stock	11/26/2008		P		560,000 (5)	A	\$ 1.93	12,411,653 (6)	I	See footnotes (1) (2)
Common	11/26/2008		P		98,000	A	\$	12,509,653	I	See

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Stock			<u>(3)</u>		1.9727	<u>(6)</u>			footnotes (1) (2)
Common Stock	11/26/2008	P	<u>68,000</u> (4)	A	\$ 1.9727	<u>12,577,653</u> (6)	I		See footnotes (1) (2)
Common Stock	11/26/2008	P	<u>242,000</u> (5)	A	\$ 1.9727	<u>12,819,653</u> (6)	I		See footnotes (1) (2)
Common Stock	11/28/2008	P	<u>56,600</u> (3)	A	\$ 1.9934	<u>12,876,253</u> (6)	I		See footnotes (1) (2)
Common Stock	11/28/2008	P	<u>40,000</u> (4)	A	\$ 1.9934	<u>12,916,253</u> (6)	I		See footnotes (1) (2)
Common Stock	11/28/2008	P	<u>144,000</u> (5)	A	\$ 1.9934	<u>13,060,253</u> (6)	I		See footnotes (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 6)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Code	V	(A)	(D)

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

- (5) Shares directly beneficially owned by Investments.
- (6) Total amount of shares indirectly beneficially owned by Partners and BVF Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.